DK1297851T3 - Inhibering af histondeacetylasesom behandling af hjertehypertrofi - Google Patents

Inhibering af histondeacetylasesom behandling af hjertehypertrofi

Info

Publication number
DK1297851T3
DK1297851T3 DK02021676T DK02021676T DK1297851T3 DK 1297851 T3 DK1297851 T3 DK 1297851T3 DK 02021676 T DK02021676 T DK 02021676T DK 02021676 T DK02021676 T DK 02021676T DK 1297851 T3 DK1297851 T3 DK 1297851T3
Authority
DK
Denmark
Prior art keywords
cardiac hypertrophy
inhibition
treatment
histone deacetylase
gene expression
Prior art date
Application number
DK02021676T
Other languages
Danish (da)
English (en)
Inventor
Michael R Bristow
Carlin Long
Timothy A Mckinsey
Eric N Olson
Original Assignee
Univ Colorado
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado, Univ Texas filed Critical Univ Colorado
Application granted granted Critical
Publication of DK1297851T3 publication Critical patent/DK1297851T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK02021676T 2001-09-27 2002-09-27 Inhibering af histondeacetylasesom behandling af hjertehypertrofi DK1297851T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32531101P 2001-09-27 2001-09-27
US33404101P 2001-10-31 2001-10-31

Publications (1)

Publication Number Publication Date
DK1297851T3 true DK1297851T3 (da) 2005-05-30

Family

ID=26984878

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02021676T DK1297851T3 (da) 2001-09-27 2002-09-27 Inhibering af histondeacetylasesom behandling af hjertehypertrofi

Country Status (8)

Country Link
US (4) US6706686B2 (OSRAM)
EP (1) EP1297851B1 (OSRAM)
JP (2) JP2003238445A (OSRAM)
AT (1) ATE287731T1 (OSRAM)
DE (1) DE60202727T2 (OSRAM)
DK (1) DK1297851T3 (OSRAM)
ES (1) ES2236415T3 (OSRAM)
PT (1) PT1297851E (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2350086A1 (en) * 1998-11-10 2000-05-18 Board Of Regents, The University Of Texas System Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
JP2001149081A (ja) * 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040171118A1 (en) * 2003-02-13 2004-09-02 City Of Hope Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
MXPA05012619A (es) * 2003-05-21 2006-02-08 Univ Texas Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005074941A1 (en) * 2004-02-02 2005-08-18 Myogen, Inc. Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
CA2561954A1 (en) * 2004-04-05 2005-10-20 Myogen, Inc. Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
EP1740945B1 (en) 2004-04-07 2018-09-19 Ncardia AG Non-invasive, in vitro functional tissue assay systems
WO2005108598A1 (en) 2004-05-11 2005-11-17 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
US20060110390A1 (en) * 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2596015A1 (en) 2005-02-14 2006-08-24 Sampath K. Anandan Fused heterocyclic compounds useful as inhibitors of histone deacetylase
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
CA2614959A1 (en) * 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
US20090012066A1 (en) * 2005-08-10 2009-01-08 Novartis Ag Method of Use of Deacetylase Inhibitors
US7863414B2 (en) * 2005-11-18 2011-01-04 The Board Of Regents Of The University Of Texas Systems Methods of treatment and uses for CaMKII and its interaction with HDACs and calpain
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
EP1976835A2 (en) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007126958A2 (en) * 2006-03-29 2007-11-08 Edward Via Virginia College Of Osteopathic Medicine Tumor cell differentiation agents as chemical inhibitors and treatments for intracellular parasites
AU2007234380A1 (en) * 2006-04-06 2007-10-11 Novartis Ag Combination of organic compounds
US7696373B2 (en) * 2006-04-13 2010-04-13 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
EP2049139A4 (en) * 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc TREATMENT OF TUMORS EXPRESSING RAS
WO2007146730A2 (en) * 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
BRPI0720734A2 (pt) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
EP2102230A2 (en) * 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Purifiction of romidepsin
WO2008140708A1 (en) * 2007-05-09 2008-11-20 The Trustees Of The University Of Pennsylvania Use of hdac inhibitors for treatment of cardiac rhythm disorders
US7737175B2 (en) * 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
US9226965B2 (en) * 2007-10-05 2016-01-05 U.S. Department Of Veterans Affairs Method and composition for treating heart failure
WO2009089598A2 (en) * 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
US20100212036A1 (en) * 2008-09-30 2010-08-19 Olson Eric N Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy
WO2011032088A1 (en) 2009-09-11 2011-03-17 Arca Biopharma, Inc. Polymorphisms in the pde3a gene
AU2011279303B2 (en) 2010-07-12 2015-07-16 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
WO2012051416A1 (en) 2010-10-13 2012-04-19 Shape Pharmaceuticals, Inc. Pharmaceutical formulation for histone deacetylase inhibitors
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP4037670A4 (en) * 2019-10-03 2023-09-27 Tenaya Therapeutics, Inc. 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF
CR20220325A (es) 2019-12-20 2022-08-19 Tenaya Therapeutics Inc Fluoroalquil-oxadiazoles y sus usos
CA3216768A1 (en) 2021-05-04 2022-11-10 Jin Yang 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
CN116942822A (zh) * 2023-06-12 2023-10-27 深圳大学 Hdac2在治疗室性心律失常中的应用
CN118766882B (zh) * 2024-09-12 2025-02-21 北京大学第三医院（北京大学第三临床医学院） 用于治疗心血管疾病的制剂及其应用和制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5968981A (en) * 1995-07-28 1999-10-19 The Regents Of The University Of California Retinoid suppression of ventricular muscle cell hypertrophy
ATE275956T1 (de) 1998-10-19 2004-10-15 Methylgene Inc Veränderung der dns methyltransferase durch kombinationstherapie
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
WO2001014581A2 (en) 1999-08-20 2001-03-01 Board Of Regents, The University Of Texas System Hdac4 and hdac5 in the regulation of cardiac gene expression
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
WO2001017514A1 (en) * 1999-09-03 2001-03-15 The Salk Institute For Biological Studies Modulation of gene expression by modulating histone acetylation
CA2383798A1 (en) 1999-09-07 2001-03-15 Conjuchem Inc. Pulmonary delivery for bioconjugation
DE60034688T2 (de) 1999-09-08 2008-01-17 Sloan-Kettering Institute For Cancer Research Kristallstruktur einer deacetylase und deren inhibitoren
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
WO2001042437A2 (en) 1999-12-08 2001-06-14 Axys Pharmaceuticals, Inc. Histone deacetylase-8 proteins, nucleic acids, and methods of use
WO2003006652A2 (en) 2000-03-24 2003-01-23 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
EP2083005A1 (en) 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
WO2002050285A2 (en) 2000-12-20 2002-06-27 Novartis Ag Histone deacetylase-related gene and protein
AR035513A1 (es) 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

Also Published As

Publication number Publication date
US20030144340A1 (en) 2003-07-31
US20060069014A1 (en) 2006-03-30
ES2236415T3 (es) 2005-07-16
JP2010001311A (ja) 2010-01-07
EP1297851A1 (en) 2003-04-02
DE60202727T2 (de) 2005-12-29
US20060025333A1 (en) 2006-02-02
ATE287731T1 (de) 2005-02-15
JP2003238445A (ja) 2003-08-27
PT1297851E (pt) 2005-06-30
US6946441B2 (en) 2005-09-20
US20040186049A1 (en) 2004-09-23
DE60202727D1 (de) 2005-03-03
US6706686B2 (en) 2004-03-16
EP1297851B1 (en) 2005-01-26

Similar Documents

Publication Publication Date Title
DK1297851T3 (da) Inhibering af histondeacetylasesom behandling af hjertehypertrofi
DK1233958T3 (da) Hæmmere af histondeacetylase
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
ATE463490T1 (de) Histondeacetylase-hemmer
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE489360T1 (de) Inhibitoren der histon-deacetylase
DE69924135D1 (de) Heterozyklische kalium-kanal inhibitoren
DE60313624D1 (de) Derivate von heteroarylnitrilverbindungen
EA200802329A1 (ru) Производные триазола ii
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
MXPA04002397A (es) Inhibidores de histona deacetilasa.
DE60336014D1 (de) Pyrrolobenzodiazepine zur behandlung proliferativer erkrankungen
EA200970486A1 (ru) Соединения для ингибирования митоза
EA200701782A3 (ru) Производные азаспироалканов в качестве ингибиторов металлопротеаз
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
TW200716183A (en) Parakeratosis inhibitor, pore-contracting agent and external composition for skin
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
IN2005KO00312A (OSRAM)
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
ATE443044T1 (de) Tace inhibitoren
DK1511472T3 (da) Anvendelige forbindelser til behandling af Anthrax og hæmning af letalfaktor
EA201200764A1 (ru) Производные хиназолина
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
EA200970812A1 (ru) Способ лечения и предупреждения артрита